MedTrace Logo

Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study

NCT00604383 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 685

Last updated 2016-10-06

Study results available
· View outcomes & findings →

Summary

This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.

Conditions

Interventions

DRUG

ruboxistaurin

32-mg tablet, orally, daily, up to 42 months

DRUG

placebo

1 tablet, orally, daily, up to 42 months

Sponsors & Collaborators

  • Chromaderm, Inc.

    lead INDUSTRY

Principal Investigators

  • Karl Beutner · Chromaderm, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-03-31
Primary Completion
2005-06-30
Completion
2005-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00604383 on ClinicalTrials.gov